The ACD440 project is in the clinical development phase, and the company’s aim is to develop a new topical local treatment for neuropathic pain. The mechanism of action of the project is via VR1 receptors, which have a key role in pain signaling.
The ACD440 project is an important strategic in-licensing that was carried out in January 2020 which fits well into the company’s existing pipeline and strengthens the clinical portfolio. The ACD440 project has its origins in Big Pharma and is based on strong scientific grounds. The substance has previously undergone phase I clinical trials, in which both tolerability and early efficacy endpoints were observed.
The VR1 receptor is expressed in sensory neurons and is upregulated in the skin of individuals with certain types of neuropathic pain. Consequently, there is strong scientific support for local treatment with this type of target mechanism.
Neuropathic pain is associated with impaired quality of life and current treatments rarely provide adequate pain relief. In all, an estimated 7–8 percent of the adult population worldwide, which corresponds to about 25 million people in Europe, Japan and the US alone, suffers from pain with neuropathic elements. About 50 percent of patients do not respond to current first-line treatment and it is specifically toward this group of individuals that AlzeCure is aiming its new intended treatment.